OTCMKTS:ALXA - Alexza Pharmaceuticals Stock Price, News, & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Sign in or create an account to add this stock to your watchlist.
Previous Close$0.9350
Today's Range$0.9350 - $0.9350
52-Week Range$0.22 - $1.60
Volume100 shs
Average Volume158,340 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Alexza Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development and commercialization of products for the acute treatment of central nervous system conditions. The Company's product candidates are based on the Staccato system technology. Its product candidates in development include AZ-002, which contains alprazolam as an active pharmaceutical ingredient (API) is developed for the management of patients with acute repetitive seizures, and AZ-007, which contains zaleplon as API is developed for the treatment of insomnia in patients who have difficulty falling asleep, including those patients with middle of the night awakening having difficulty falling back asleep. Its product also includes ADASUVE, which contains loxapine as API is developed for the treatment of agitation associated with schizophrenia or bipolar disorder. It has initiated a Phase IIa proof-of-concept study for AZ-002 in patients with epilepsy and has completed Phase I testing for AZ-007.

Receive ALXA News and Ratings via Email

Sign-up to receive the latest news and ratings for ALXA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Current SymbolOTCMKTS:ALXA
Previous SymbolNASDAQ:ALXA



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Alexza Pharmaceuticals (OTCMKTS:ALXA) Frequently Asked Questions

What is Alexza Pharmaceuticals' stock symbol?

Alexza Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ALXA."

How were Alexza Pharmaceuticals' earnings last quarter?

Alexza Pharmaceuticals, Inc. (OTCMKTS:ALXA) posted its earnings results on Wednesday, May, 11th. The healthcare company reported ($0.16) EPS for the quarter. The healthcare company had revenue of $0.72 million for the quarter. View Alexza Pharmaceuticals' Earnings History.

Has Alexza Pharmaceuticals been receiving favorable news coverage?

Media headlines about ALXA stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Alexza Pharmaceuticals earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave news stories about the healthcare company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

What other stocks do shareholders of Alexza Pharmaceuticals own?

What is Alexza Pharmaceuticals' official website?

The official website for Alexza Pharmaceuticals is http://www.alexza.com/.

How can I contact Alexza Pharmaceuticals?

Alexza Pharmaceuticals' mailing address is 2091 Stierlin Ct, MOUNTAIN VIEW, CA 94043-4655, United States. The healthcare company can be reached via phone at +1-650-9447000.

MarketBeat Community Rating for Alexza Pharmaceuticals (OTCMKTS ALXA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  296
MarketBeat's community ratings are surveys of what our community members think about Alexza Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALXA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALXA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/21/2019 by MarketBeat.com Staff

Featured Article: Candlestick

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel